2022 Revenues ($USD) : $1,035,365,000 2022 R&D spend : $183,414,000 2022 Number of Employees : 3,000 Fiscal Year End : 12/31/2021 Company CEO : Damien McDonald, CEO
London-based LivaNova develops devices used for cardiac surgery and neuromodulation. Formed in 2015 through a merger between Houston-based Cyberonics and Milan, Italy–based Sorin, the company currently employs 3,000 people worldwide, according to its most recent annual report. In its most recent quarter (ended June 30, 2022), LivaNova company posted profits of $16.4 million, or 30¢ per share, on sales of $254.2 million. The company earlier this year launched a patient monitor for cardiopulmonary bypass procedures. –SW